About Us

On September 1st, 2022, Advanced Biological Laboratories Fedialis SAS (formerly ABL France SAS) merged into ABL Diagnostics SA (ABLD), a worldwide leading international company listed on Euronext Paris compartment C (ISIN FR001400AHX6), offering innovative and proprietary molecular biology assays and end-to-end solutions intended to be used for molecular detection by Polymerase Chain Reaction (PCR) - UltraGene® and for genotyping through DNA sequencing - DeepChek® (a very sensitive, robust and sustainable technology allowing precise identification of relevant genomic variations like single nucleotide polymorphisms (SNP), amino-acid mutations, quasispecies like variants of concern, already published or which will be discovered in the future, with known impact on disease prognosis, drug efficacy, pathogen activity…).

These molecular biology products are generating recurring revenues and cover one of the largest portfolios of microbiology applications, growing fast year after year to stick to the market needs, with a primary focus on HIV (with CE-IVD marked target-specific assays covering all relevant genes used for drug resistance assessment like reverse transcriptase, protease, integrase and with disruptive Whole Genome Kits), on SARS-CoV-2 (with a CE-IVD marked Whole Genome assay), on Tuberculosis (with a CE-IVD marked multiplex assay targeting genes relevant for first line, second line and new-drugs resistance determination), on viral hepatitis B and C, 16s/18s RNA for taxonomy and microbiome analyses and other viral and bacterial targets. Please consult the ABL team for further information about the registration status of ABLD’s products in your territory.

ABLD commercialises its entire line of products on a worldwide basis through its own sales team and through a network of exclusive distributors active on all continents. ABLD clients are academic clinical pathology labs, private reference labs and researchers willing to implement an innovative and robust microbiology content in constant expansion.

ABLD also develops, manufactures and markets kits for clinical specimen collection – MediaChek® and digital solutions like Nadis®, a CE-marked Electronic Medical Record (EMR) system used in France in more than 200 hospitals managing patients infected by HIV or Viral Hepatitis.

Since 2019, the activities of ABL DIAGNOSTICS have also been carried out in the United States through its wholly owned subsidiary, ABL ADVANCEDDX BIOLOGICAL LABORATORIES USA Inc.

For more information, visit www.abldiagnostics.com.
Contacts
ABL DIAGNOSTICS
72C Route de Thionville
57140 WOIPPY
France
Phone: +33 145 061 574
Email: contact@abldiagnostics.com


Press releases

ABL Diagnostics and AB ANALITICA join forces to offer microbiology...

Woippy (France) – ABL Diagnostics (FR001400AHX6 – ABLD, the “Company”) , a Euronext-listed company that develops molecular biology assays and... read more

28.02.2024 • By ABL Diagnostics SA

Carrying Out Research About HIV Whole Genome using a Kit Now Available...

Access to a comprehensive Next Generation Sequencing (NGS) kit for HIV Whole Genome genotyping. Ability to screen genomic variations in all... read more

28.02.2024 • By ABL Diagnostics SA

AdvancedDx Biological Laboratories USA Inc. announces its new...

Newburyport (MA, USA) – AdvancedDx Biological Laboratories USA Inc., an affiliate of ABL Diagnostics (FR001400AHX6 – ABLD, the “Company”), a... read more

20.02.2024 • By ABL Diagnostics SA

ABL Diagnostics désigne un nouveau directeur général

Woippy (France) – ABL Diagnostics (FR001400AHX6 – ABLD)  annonce la désignation du Dr Chalom Sayada, fondateur et CEO de la société Advanced... read more

31.01.2024 • By ABL Diagnostics SA

ABL Diagnostics announces the release of its DeepChek®-HPV Assay, to be...

Next Generation Sequencing (NGS) assay and software to screen, to genotype and to discriminate the Human Papillomavirus. ABL Diagnostics... read more

18.01.2024 • By ABL Diagnostics SA

ABL Diagnostics announces new releases of its DeepChek®, ViroScore® and...

ABL Diagnostics uses its application-specific expertise to provide Information System (IT) services & software applications to all... read more

03.01.2024 • By ABL Diagnostics SA

ABL DIAGNOSTICS INTRODUCING CRISPRCHEK - A NEW LINE OF ASSAYS USING THE...

ABL Diagnostics keeps innovating and developing its Research & Development activities through a new line of PCR detection assays, called... read more

18.12.2023 • By ABL Diagnostics SA

ABL Diagnostics releases new applications for respiratory viruses...

ABL Diagnostics strengthens its DeepChek® portfolio with new genotyping applications for Influenza A/B and RSV A/B. Verified on Next... read more

06.12.2023 • By ABL Diagnostics SA

ABL DIAGNOSTICS EXPANDS ITS HIV GENOTYPING ASSAYS OFFERING

ABL Diagnostics keeps investing to strengthen its expertise and leadership in HIV drug resistance testing by genotyping through the release of a... read more

30.11.2023 • By ABL Diagnostics SA

ABL Diagnostics expands its commercial network and collaborations to...

ABL Diagnostics spreading the DeepChek® technology (suite of Sanger & NGS assays and software systems) to laboratories performing infectious... read more

24.11.2023 • By ABL Diagnostics SA

ABL Diagnostics reçoit une subvention de l’Etat et de la Région Grand...

Woippy, le 13 Juillet 2023 - ABL Diagnostics SA (ABL) annonce aujourd’hui l’accord de l’Etat et de la Région Grand Est, dans le cadre de l’appel... read more

13.07.2023 • By ABL Diagnostics SA

ABL Diagnostics : Renouvellement de 4 ans du contrat AP-HP* pour...

Woippy, le 30 Juin 2023 - ABL Diagnostics SA (ABL) annonce aujourd’hui le renouvellement du contrat de marché relatif au logiciel Nadis®, établi... read more

30.06.2023 • By ABL Diagnostics SA

Roche Diagnostics (Pty) Ltd and ABL Diagnostics enter into an Exclusive...

Johannesburg (South Africa), Woippy (France) — March 27th 2023 Roche Diagnostics (Pty) Ltd (Roche SA) and ABL Diagnostics (ABLD) are pleased... read more

27.03.2023 • By ABL Diagnostics SA

The Luxembourg Institute of Health and Advanced Biological Laboratories...

The Luxembourg Institute of Health (LIH ) and Advanced Biological Laboratories (ABL) are joining forces to predict immune protection against... read more

10.01.2022 • By ABL Diagnostics SA

Acquisition of a controlling stake in ETABLISSEMENTS FAUVET GIREL by...

15 October 2021 Acquisition of a controlling stake in Etablissements Fauvet Girel by Advanced Biological Laboratories ETABLISSEMENTS... read more

19.10.2021 • By ABL Diagnostics SA

Advanced Biological Laboratories Receives CE-IVD Registration for its...

Advanced Biological Laboratories (ABL) announced today the CE-IVD registration of its UltraGene Assay SARS-CoV-2 452R & 484K & 484Q... read more

31.08.2021 • By ABL Diagnostics SA

Advanced Biological Laboratories Obtained a Derogatory Authorization...

Advanced Biological Laboratories (ABL) announced today the obtention of a derogatory authorization from the French National Agency for Medicines... read more

22.06.2021 • By ABL Diagnostics SA

Advanced Biological Laboratories Receives CE Registration for its NADIS...

Advanced Biological Laboratories (ABL) and Fédialis Médica announced today the CE registration of its NADIS® Software which is a specialty... read more

07.06.2021 • By ABL Diagnostics SA

Advanced Biological Laboratories Receives CE-IVD Registration for its...

Advanced Biological Laboratories (ABL) announced today the CE-IVD registration of its DeepChek® Whole Genome SARS-CoV-2 Genotyping Assay ,... read more

25.05.2021 • By ABL Diagnostics SA

Advanced Biological Laboratories Receives CE-IVD Registration for its...

Advanced Biological Laboratories (ABL) announced today the CE-IVD registration of its UltraGene® SARS-CoV-2 Triplex Assay, now available for... read more

26.04.2021 • By ABL Diagnostics SA

Advanced Biological Laboratories (ABL) Releases the First & Unique...

Advanced Biological Laboratories (ABL) announced today the CE-IVD marking of its UltraGene® Combo2Screen SARS-CoV-2 qPCR assay. It is the first... read more

06.07.2020 • By ABL Diagnostics SA

SARS-CoV-2 PCR Assay Now Approved for Human Saliva Specimens

Advanced Biological Laboratories (ABL) announced today the validation of its CE-IVD UltraGene® Combo2Screen SARS-CoV-2 qPCR assay to be used... read more

17.06.2020 • By ABL Diagnostics SA

Advanced Biological Laboratories Receives CE-IVD Registration for its...

Luxembourg (Luxembourg), Metz (France) — May 21 — Advanced Biological Laboratories (ABL) announced today the CE-IVD registration of its... read more

21.05.2020 • By ABL Diagnostics SA

Contact